Metabolic and toxicological considerations for obsessive-compulsive disorder drug therapy

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 6, 2013, Pages 657-673

  Sayyah, Mohammad ^a   Majzoob, Sayeh ^b   Sayyah, Mehdi ^c  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b Expert in Pharmaceutical Industry   (Iran)

^c AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Drug therapy; Metabolism; OCD; SNRIs; SSRIs; TCAs; Toxicity

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450; DESVENLAFAXINE; DIGOXIN; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; OLANZAPINE; PAROXETINE; PHENYTOIN; QUETIAPINE; RISPERIDONE; SEROTONIN 2 RECEPTOR; SEROTONIN AGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; WARFARIN;

ANORGASMIA; ANXIETY; CONVULSION; DEPRESSION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; EJACULATION DISORDER; ERECTILE DYSFUNCTION; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; INSOMNIA; IRRITABILITY; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LIBIDO; LIVER DYSFUNCTION; LIVER METABOLISM; MAINTENANCE THERAPY; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PRACTICE GUIDELINE; PSYCHOPHARMACOTHERAPY; QT PROLONGATION; RESPIRATORY DISTRESS; REVIEW; RISK FACTOR; SEIZURE; SEROTONIN SYNDROME; SIDE EFFECT; SUICIDAL IDEATION; TREATMENT DURATION; WITHDRAWAL SYNDROME;

ADRENERGIC UPTAKE INHIBITORS; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS;

EID: 84877852272     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.783011     Document Type: Review

References (84)

1. Stein DJ. Obsessive-compulsive disorder. Lancet 2002;360:397-405.
2. Hollander E. Obsessive-compulsive disorder: the hidden epidemic. J Clin Psychiatry 1997;58(Suppl 12):3-6.
3. Bebbington PE. Epidemiology of obsessive-compulsive disorder. Br J Psychiatry Suppl 1998;35:2-6.
4. Fernandez-Cordoba E, Lopez-Ibor Alino J. La monoclomipramina en enfermos psiquiatricos resistentes a ostros tratamientos. Acta Luso Esp Neurol Psiquiatr Cienc Afines 1967;26:119-47.
5. Stein DJ, Hollander E. Serotonin specific re-uptake inhibitors in obsessive-compulsive disorder and related disorders. In: Feighner JP, Boyer WF, editors. Selective serotonin reuptake inhibitors. 2nd edition. Wiley, Chichester; 1996. p. 135-53.
6. Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Arch Gen Psychiatry 1995;52:53-60.
7. Piccinelli M, Pini S, Bellantuono C, et al. Efficacy of drug treatment in obsessive-compulsive disorder: a meta-analytic review. Br J Psychiatry 1995;166:424-43.
8. Ravizza L, Barzega G, Bellino S, et al. Drug treatment of obsessive-compulsive disorder: long-term trial with clomipramine and selective serotonin reuptake inhibitors. Psychopharmacol Bull 1996;32:167-73.
9. Stein DJ, Spandaccini E, Hollander E. Meta-analysis of pharmacotherapy trials for obsessive-compulsive disorder. Int Clin Psychopharmacol 1995;10:11-18.
10. Pigott TA, Pato MT, Bernstein SE, et al. Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1990;47:926-32.
11. Tamini RR, Mavissakalian MR, Jones V, et al. Clomipramine versus fluvoxamine in obsessive-compulsive disorder. Ann Clin Psychiatry 1991;3:275-9.
12. Leonard HL. New developments in the treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997;58(Suppl 14):39-45.
13. Pato MT, Zohar-Kadouch R, Zohar J, et al. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry 1988;145:1521-5.
14. Pato MT, Murphy DL, DeVane CL. Sustained plasma concentrations of fluoxetine and/or norfluoxetine for eight weeks after fluoxetine discontinuation. J Clin Psychopharmacol 1991;11:224-5.
15. McDougle CJ, Goodman WK, Leckman JF, et al. The psychopharmacology of obsessive-compulsive disorder: implications for treatment and pathogenesis. Psychiatr Clin North Am 1993;16:749-66.
16. Dell'Osso B, Nestadt G, Allen A, et al. Serotonin-norepinephrine reuptake inhibitors in the treatment of obsessive-compulsive disorder: a critical review. J Clin Psychiatry 2006;67:600-10.
17. Sansone RA, Sansone LA. SNRIs Pharmacological alternatives for the treatment of obsessive compulsive disorder? Innov Clin Neurosci 2011;8:10-14.
18. Ravizza L, Barzega G, Bellino S, et al. Drug treatment of obsessive compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacol Bull 1996;32:167-73.
19. Marazziti D, Golia F, Consoli G, et al. Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients. CNS Spectr 2008;13:971-6.
20. Bandelow B, Zohar J, Hollander E, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders first revision. W J Biol Psychiatry 2008;9:248-312.
21. Stein DJ, Koen N, Fineberg N, et al. A 2012 evidence-based algorithm for the pharmacotherapy for obsessive-compulsive disorder. Curr Psychiatry Rep 2012;4:211-19.
22. Maher AR, Theodore G. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. J Manag Care Pharm 2012;18(5 Suppl B):1-20.
23. Pittenger C, Bloch MH, Willams K. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology and treatment. Pharmacol Ther 2011;132:314-32.
24. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996;31:444-69.
25. O'Donnell JM, Shelton RC. Drug therapy of depression and anxiety disorders. In: Brunton LL, Chabner BA, Bjorn K, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 12th edition. The McGraw-Hill Companies, Inc, New York; 2011. p. 397-415.
26. Targownik LE, Bolton JM, Metge CJ, et al. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 2009;104:1475-82.
27. British National Formulary 61. 64th edition. Pharmaceutical Press, London; March 2012.
28. Schneeweiss S, Patrick AR, Solomon DH, et al. Comparative safety of antidepressant agents for children and adolescents regarding suicidal acts. Pediatrics 2010;125:876-88.
29. Bronstein AC, Spyker DA, Cantilena LR. Jr, et al. 2009 annual report of the American association of poison control centers' national poison data system (NPDS): 27th annual report. Clin Toxicol (Phila) 2010;48:979-1178.
30. Nelson LS, Erdman AR, Booze LL, et al. Selective serotonin reuptake inhibitor poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2007;45:315-22.
31. Warden SJ, Bliziotes MM, Wiren KM, et al. Neural regulation of bone and the skeletal effects of serotonin (5-hydroxytryptamine). Mol Cell Endocrinol 2005;242:1-9.
32. Chen F, Hahn TJ, Weintraub NT. Do SSRIs play a role in decreasing bone mineral density? J Am Med Dir Assoc 2012;13:413-17.
33. Ziere G, Dieleman JP, van der Cammen TJ, et al. Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol 2008;28:411-17.
34. FDA Drug Safety Communication: selective serotonin reuptake inhibitor (SSRI) antidepressant use during pregnancy and reports of a rare heart and lung condition in newborn babies. Available from: http://www.fda.gov/drugs/ drugsafety/ucm283375.htm.
35. Hiemke C, Haertter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000;85:11-28 Dtsch Arztebl Int 2011;108:687-93.
36. Targownik LE, Bolton JM, Metge CJ, et al. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. Am J Gastroenterol 2009;104:1475-82.
37. ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 354. Treatment with selective serotonin reuptake inhibitors during pregnancy. Obstet Gynecol 2006;108:1601-3.
38. Berle JO, Spigset O. Antidepressant use during breastfeeding. Curr Womens Health Rev 2011;7(1):28-34.
39. Physicians' desk reference. 66th edition. PDR network, New Jersey; 2012.
40. Flanagan RJ. Fatal toxicity of drugs used in psychiatry. Hum Psychopharmacol 2008;23:43-51.
41. Kelly CA, Dhaun N, Laing WJ, et al. Comparative toxicity citalopram and the newer antidepressants after overdose. Clin Toxicol 2005;42:67-71.
42. White N, Litovitz T, Clancy C. Suicidal antidepressant overdose: a comparative analysis by antidepressant type. J Med Toxicol 2008;4:238-50.
43. Hayes BD, Klein-Schwartz W, Clark RF, et al. Comparison of toxicity of acute overdoses with citalopram and escitalopram. J Emerg Med 2010;39:44-8.
44. Hawton K, Bergen H, Simkin S, et al. Toxicity of antidepressants: rates of suicide relative to prescribing and non-fatal overdose. Br J Psychiatry 2010;196:354-8.
45. FDA drug safety communication: revised recommendation for Celexa (citalopram hydrobromide) related to a potential risk of abnormal heart rhythms with high doses. Available from: http://www.fda. gov/drugs/drugsafety/ucm297391. htm.
46. Forrester MB. Escitalopram ingestions reported to Texas poison control centers, 2002-2005. Hum Exp Toxicol 2004;26:473-82.
47. Abudy A, Juven-Wetzler A, Zohar A. Pharmacological management of treatment-resistant obsessive-compulsive disorder. CNS Drugs 2011;25:585-96.
48. van Gorp F, Whyte IM, Isbister GK. Clinical and ECG effects of escitalopram overdose. Ann Emerg Med 2009;54:404-8.
49. Mamiya K, Kojima K, Yukawa E, et al. Phenytoin intoxication induced by fluvoxamine. Ther Drug Monit 2001;23:75-7.
50. Fritze J, Unsorg B, Lanczik M. Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand 1991;84:583-4.
51. Garnier R, Azoyan P, Chataigner D, et al. Acute fluvoxamine poisoning. J Int Med Res 1993;21:197-208.
52. Available from: http://www.drugs.com/pro/anafranil.html.
53. De Carvalho SC, Marcourakis T, Artes R, et al. Memory performance in panic disorder patients after chronic use of clomipramine. J Psychopharmacol 2002;16:220-6.
54. Dell'Osso B, Mundo E, Marazziti E, et al. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive-compulsive disorder: a case series. J Psychopharmacol 2008;22:210-13.
55. Available from: http://www.drugs.com/pro/venlafaxine.html.
56. Whyte IM, Dawson AH, Buckley NA. Relative toxicity of venlafaxine and serotonin specific reuptake inhibitors in overdose compared to tricyclic antidepressants. QJM 2003;96:369-74.
57. Khalifa M, Deleau P, Turgeon J. Mechanism of sodium channel block in guinea pig ventricular myocytes. J Pharmacol EXP Ther 1999;291:280-4.
58. Bosse GM, Spiller HA, Collins AM. A fatal case of venlafaxine overdose. J Med Toxicol 2008;4:18-20.
59. Prasko J, Latalova K, Grambal A, et al. Off-label use of second generation antipsychotics in anxiety disorders and obsessive compulsive disorder. Act Nerv Super Rediviva 2010;52:229-40.
60. Bloch MH, Landeros-Weisenberger A, Kelmedi B, et al. A systematic review: antipsychotic augmentation with treatment-refractory obsessive-compulsive disorder. Mol Psychiatry 2006;11:622-32.
61. Ipser JC, Carey P, Dhansay Y, et al. Pharmacotherapy augmentation strategies in treatment resistant anxiety disorders. Cochrane Database Syst Rev 2006;CD005473.
62. Fineberg NA, Gale TM, Sivakumaran T. A review of antipsychotics in the treatment of obsessive compulsive disorder. J Psychopharmacol 2006;20:97-103.
63. Skapinakis P, Papatheodorou T, Mavreas V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur Neuropsychopharmacol 2007;17:79-93.
64. Kellner M. Drug treatment of obsessive-compulsive disorder. Dialogues Clin Neurosci 2010;12:187-97.
65. Dold M, Aigner M, Lanzenberger R, et al. Efficacy of antipsychotic augmentation therapy in treatment-resistant obsessive-compulsive disorder: a meta-analysis of double-blind, randomized placebo-controlled trials. Fortschr Neurol Psyhiatr 2011;79:453-66.
66. Vasile D, Vasiliu O, Mangalagiu AG, et al. Augmentation strategies in selective serotonin reuptake inhibitors resistant obsessive-compulsive disorder: a systematic literature review. Ther Pharmacol Clin Toxicol 2011;15:83-92.
67. Meyer JM. Pharmacotherapy of psychosis and mania. In: Brunton LL, Chabner BA, Bjorn K, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 12th edition. The McGraw-Hill Companies, Inc, New York; 2011. p. 417-55.
68. Available from: http://www.drugs.com/pro/risperidone.html.
69. Weiden PJ. EPS profiles: the atypical antipsychotics are not all the same. J Psychiatr Pract 2007;13:13-24.
70. Tan HH, Hope J, Heard K. A systematic review of cardiovascular effects after atypical antipsychotic medication overdose. Am J Emerg Med 2009;27:607-16.
71. Novick D, Haro JM, Perrin E, et al. Tolerability of outpatient antipsychotic treatment: 36-month results from the European schizophrenia outpatient health outcomes (SOHO) study. Eur Neuropsychopharmacol 2009;19:542-50.
72. Available from: http://www.drugs.com/pro/seroquel.html.
73. Stephani T, Trenkwalder C. Rhabdomyolysis after low dose quetiapine in a patient with Parkinson's disease drug-induced psychosis: a case report. Mov Disord 2010;25:790-1.
74. Dickmann JR, Dickmann LM. An uncommonly recognized cause of rhabdomyolysis after quetiapine intoxication. Am J Emerg Med 2010;28:1060.e1-2.
75. Eyer F, Pfab R, Felgenhauer N, et al. Clinical and analytical features of severe suicidal quetiapine overdoses: a retrospective cohort study. Clin Toxicol 2011;49:846-53.
76. Kumlien E, Lundberg PO. Seizure risk associated with neuroactive drugs: data from the WHO adverse drug reactions database. Seizure 2010;19:69-73.
77. Ngo A, Ciranni M, Olson KR. Acute quetiapine overdose in adults: a 5-year retrospective case series. Ann Emerg Med 2008;52:541-7.
78. Ciranni MA, Kearney TE, Olson KR. Comparing acute toxicity of first- and second-generation antipsychotic drugs: a 10 year, retrospective cohort study. J Clin Psychiatry 2009;70:122-9.
79. Anita SX, Sholevar EH, Baron DA. Overdoses and ingestions of second-generation antipsychotics in children and adolescents. J Child Adolesc Psychopharmacol 2005;15:970-85.
80. Available from: http://www.drugs.com/pro/zyprexa.html.
81. Rabinowitz J, Brauch Y, Barak Y. High dose escitalopram for the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 2008;23:49-53.
82. Zohar J. Escitalopram in the treatment of obsessive-compulsive disorder. Expert Rev Neurother 2008;8:339-49.
83. Ninan PT, Koran LM, Kiev A, et al. High dose sertraline strategy for nonresponders to acute treatment of obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry 2006;67:15-22.
84. Serretti A, Mandelli L. Antidepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010;71:1259-72.